Industries > Pharma > Global Ophthalmic Drugs Market Forecast 2017-2027

Global Ophthalmic Drugs Market Forecast 2017-2027

Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs

PUBLISHED: 14 June 2017
PAGES: 306
PRODUCT CODE: PHA0202
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0202 Categories: , Tag:

The global ophthalmic drugs market is expected to grow at a CAGR of 4.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.6% from 2017-2027. The market is estimated at $23bn in 2016 and $28.1bn in 2021. In 2016, the retinal disorder drugs submarket held 40% of the share in this market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 306-page report you will receive 125 tables and 113 figures – all unavailable elsewhere.

The 306-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Ophthalmic Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecasts to 2027 for the global ophthalmic drugs market by the leading submarkets:
– Retinal Disorder Drugs
– Allergic, Inflammatory & Infective Drugs
– Glaucoma Drugs
– Dry Eye Drugs
– Other Ophthalmic Drugs

Global Ophthalmic Drugs Market Forecast 2017-2027

• This report includes revenue forecasts to 2027 for the following ophthalmic drugs:
– Eylea
– Lucentis
– Avastin
– Visudyne
– Jetrea
– Pataday
– Vigamox
– Patanol
– TobraDex
– Cravit
– AzaSite
– Acular
– Lumigan and Ganfort
– Xalatan/Xalacom
– Travatan/Travatan Z and DuoTrav
– Alphagan/Alphagan P and Combigan
– Azopt
– Trusopt
– Zioptan
– Cosopt
– Tapros/Taflotan
– Restasis
– Refresh
– Hyalein
– Diquas

• This report provides individual revenue forecasts to 2027 for these national markets:
– The US
– Japan
– EU5: Germany, France, the UK, Spain, Italy
– Russia
– China
– India
– Brazil
– Rest of the World

• Our study provides a SWOT analysis and discusses Porter’s Five Forces analysis that influence the global ophthalmic drugs market

• Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

• Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
– Novartis
– Regeneron
– Allergan
– Roche
– Valeant
– Santen
– Bayer
– Pfizer
– Senju

Visiongain’s study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Ophthalmic Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ